Literature DB >> 1991714

Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.

L P Perera1, J E Samuel, R K Holmes, A D O'Brien.   

Abstract

Shiga toxin of Shigella dysenteriae type I and Shiga-like toxins I and II (SLT-I and SLT-II, respectively) of enterohemorrhagic Escherichia coli are functionally similar protein cytotoxins. These toxin molecules have a bipartite molecular structure which consists of an enzymatically active A subunit that inhibits protein synthesis in eukaryotic cells and an oligomeric B subunit that binds to globotriaosylceramide glycolipid receptors on eukaryotic cells. Regionally directed chemical mutagenesis of the B subunit of SLT-II was used to identify amino acids in the B subunit that are critical for SLT-II holotoxin cytotoxic activity. Three noncytotoxic mutants were isolated, and their mutations were mapped. The substitutions of arginine with cysteine at codon 32, alanine with threonine at codon 42, and glycine with aspartic acid at codon 59 in the 70-amino-acid mature SLT-II B polypeptide resulted in the complete abolition of cytotoxicity. The analogous arginine, alanine, and glycine residues were conserved at codons 33, 43, and 60 in the 69-amino-acid mature B polypeptide of Shiga toxin. Comparable mutations induced in the B-subunit gene of Shiga toxin by oligonucleotide-directed, site-specific mutagenesis resulted in drastically decreased cytotoxicity (10(3)- to 10(6)-fold) as compared with that of wild-type Shiga toxin. The mutant SLT-II and Shiga toxin B subunits were characterized for stability, receptor binding, immunoreactivity, and ability to be assembled into holotoxin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991714      PMCID: PMC207236          DOI: 10.1128/jb.173.3.1151-1160.1991

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  29 in total

1.  Cloning of genes for production of Escherichia coli Shiga-like toxin type II.

Authors:  J W Newland; N A Strockbine; R J Neill
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 3.  Tinkering with enzymes: what are we learning?

Authors:  J R Knowles
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

4.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

5.  Simple method for identification of plasmid-coded proteins.

Authors:  A Sancar; A M Hack; W D Rupp
Journal:  J Bacteriol       Date:  1979-01       Impact factor: 3.490

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1.

Authors:  A A Lindberg; J E Brown; N Strömberg; M Westling-Ryd; J E Schultz; K A Karlsson
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

8.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

9.  Quantitative microtiter cytotoxicity assay for Shigella toxin.

Authors:  M K Gentry; J M Dalrymple
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

10.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  7 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain.

Authors:  Alvin W H Lo; Kristof Moonens; Maia De Kerpel; Lea Brys; Els Pardon; Han Remaut; Henri De Greve
Journal:  J Biol Chem       Date:  2014-07-22       Impact factor: 5.157

3.  A major transactivator of varicella-zoster virus, the immediate-early protein IE62, contains a potent N-terminal activation domain.

Authors:  L P Perera; J D Mosca; W T Ruyechan; G S Hayward; S E Straus; J Hay
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Regulation of varicella-zoster virus gene expression in human T lymphocytes.

Authors:  L P Perera; J D Mosca; W T Ruyechan; J Hay
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences.

Authors:  A G Murzin
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

6.  CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.

Authors:  M D Maloney; C A Lingwood
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

Review 7.  Molecular Biology of Escherichia Coli Shiga Toxins' Effects on Mammalian Cells.

Authors:  Christian Menge
Journal:  Toxins (Basel)       Date:  2020-05-23       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.